Michael Yee
Stock Analyst at UBS
(4.07)
# 597
Out of 5,182 analysts
118
Total ratings
51.25%
Success rate
13.68%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgrades: Buy | $185 → $225 | $185.95 | +21.00% | 7 | Apr 22, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $90 → $60 | $51.82 | +15.79% | 3 | Apr 21, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $45 | $17.00 | +164.71% | 1 | Apr 21, 2026 | |
| AMGN Amgen | Maintains: Buy | $390 → $400 | $344.86 | +15.99% | 8 | Apr 13, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $130 → $145 | $112.56 | +28.82% | 1 | Apr 13, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $27 | $27.31 | -1.14% | 2 | Apr 13, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $50 → $75 | $69.00 | +8.70% | 3 | Apr 6, 2026 | |
| KOD Kodiak Sciences | Maintains: Buy | $50 → $80 | $46.14 | +73.39% | 5 | Mar 27, 2026 | |
| SDGR Schrödinger | Maintains: Neutral | $18 → $13 | $12.88 | +0.93% | 4 | Mar 17, 2026 | |
| NUVB Nuvation Bio | Maintains: Neutral | $10 → $7 | $5.11 | +36.99% | 5 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $115 | $114.98 | +0.02% | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $230 | $205.12 | +12.13% | 2 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $535 → $545 | $436.59 | +24.83% | 6 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $155 | $133.29 | +16.29% | 5 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $50 | $31.83 | +57.08% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $25 | $20.13 | +24.19% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $24 → $55 | $29.52 | +86.31% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $5.40 | +122.22% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $14.28 | +250.14% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $48.10 | +24.74% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.81 | +83.73% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $16.63 | +170.60% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $33.24 | +80.51% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $30.69 | -8.77% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.32 | +244.83% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.44 | +43.21% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.56 | +204.88% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $59.39 | +9.45% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $903.02 | +38.42% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $1.70 | +76.47% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $54.23 | +1.42% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $404.92 | -4.92% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.55 | -45.95% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $14.51 | +37.84% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.92 | +1,462.50% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $10.67 | +181.16% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $26.95 | +345.27% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $84.08 | -64.32% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $25.03 | +207.63% | 2 | Nov 8, 2018 |
Biogen
Apr 22, 2026
Upgrades: Buy
Price Target: $185 → $225
Current: $185.95
Upside: +21.00%
AnaptysBio
Apr 21, 2026
Maintains: Buy
Price Target: $90 → $60
Current: $51.82
Upside: +15.79%
First Tracks Biotherapeutics
Apr 21, 2026
Initiates: Buy
Price Target: $45
Current: $17.00
Upside: +164.71%
Amgen
Apr 13, 2026
Maintains: Buy
Price Target: $390 → $400
Current: $344.86
Upside: +15.99%
Merck & Co.
Apr 13, 2026
Maintains: Buy
Price Target: $130 → $145
Current: $112.56
Upside: +28.82%
Pfizer
Apr 13, 2026
Maintains: Neutral
Price Target: $25 → $27
Current: $27.31
Upside: -1.14%
Oruka Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $50 → $75
Current: $69.00
Upside: +8.70%
Kodiak Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $50 → $80
Current: $46.14
Upside: +73.39%
Schrödinger
Mar 17, 2026
Maintains: Neutral
Price Target: $18 → $13
Current: $12.88
Upside: +0.93%
Nuvation Bio
Mar 3, 2026
Maintains: Neutral
Price Target: $10 → $7
Current: $5.11
Upside: +36.99%
Feb 24, 2026
Downgrades: Neutral
Price Target: $100 → $115
Current: $114.98
Upside: +0.02%
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $205.12
Upside: +12.13%
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $436.59
Upside: +24.83%
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $133.29
Upside: +16.29%
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $31.83
Upside: +57.08%
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $20.13
Upside: +24.19%
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $29.52
Upside: +86.31%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $5.40
Upside: +122.22%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $14.28
Upside: +250.14%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $48.10
Upside: +24.74%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $3.81
Upside: +83.73%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $16.63
Upside: +170.60%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $33.24
Upside: +80.51%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $30.69
Upside: -8.77%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.32
Upside: +244.83%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $24.44
Upside: +43.21%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $6.56
Upside: +204.88%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $59.39
Upside: +9.45%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $903.02
Upside: +38.42%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.70
Upside: +76.47%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $54.23
Upside: +1.42%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $404.92
Upside: -4.92%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.55
Upside: -45.95%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $14.51
Upside: +37.84%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.92
Upside: +1,462.50%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $10.67
Upside: +181.16%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $26.95
Upside: +345.27%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $84.08
Upside: -64.32%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $25.03
Upside: +207.63%